<DOC>
	<DOCNO>NCT01810484</DOCNO>
	<brief_summary>Up 20 subject enrol . Enrolled subject receive one three study treatment abdominal region : Ultherapy® , Ultherapy® CO2 laser treatment , CO2 laser treatment . Follow-up visit occur 14 , 90 180 day post-treatment . Study image obtain pre-treatment , approximately 30 minute post-treatment , follow-up visit .</brief_summary>
	<brief_title>Feasibility Study : Evaluation Treatment Striae Using Ultherapy® Combination With Laser Treatment</brief_title>
	<detailed_description>This prospective , randomize , single-blinded , single-center , pilot clinical trial evaluate use Ulthera® System combination 70W Alma Pixel CO2 laser efficacious result treatment abdominal stria rubra stria alba . Subjects randomize one three treatment group . Study personnel conduct efficacy measure blind assign treatment group . Changes baseline overall skin texture appearance abdominal stria assess study follow-up visit . 2D image , 3D image patient satisfaction questionnaire obtain .</detailed_description>
	<criteria>Male female , age 21 65 year . Subject good health . Fitzpatrick skin classification type 15 . Striae rubra alba abdomen . Understands accepts obligation undergo procedure area ( ) treat followup period . Willingness ability comply protocol requirement , include return followup visit abstain exclusionary procedure duration study . Absence physical psychological condition unacceptable investigator . Willingness ability provide write consent studyrequired photography adherence photography requirement . Willingness ability provide write informed consent HIPAA authorization prior performance studyrelated procedure . Subjects childbearing potential must negative urine pregnancy test result must lactate Visit 1 willing able use acceptable method birth control study Presence active systemic local skin disease may affect wound healing . Current bacterial viral infection area treat . Severe solar elastosis . Significant scar burn area ( ) treat . Prior radiation therapy area ( ) treat . Open wound lesion area ( ) treat . History keloid hypertrophic scar History irregular pigmentation skin , Lichens Planus , Vitiligo Psoriasis treatment area investigator opinion , would put subject unnecessary risk . Inability understand protocol give inform consent . Microdermabrasion , prescription level glycolic acid treatment intend treatment area ( ) within two week prior study participation study . History chronic drug alcohol abuse . History autoimmune disease . Concurrent therapy , investigator 's opinion , would interfere evaluation safety efficacy study device . Subjects anticipate need surgery overnight hospitalization study . Subjects , investigator 's opinion , history poor cooperation , noncompliance medical treatment , unreliability . Concurrent enrollment study involve use investigational device drug . Current smoker history smoking last five year . History prior abdominal Suction Assisted Lipectomy Abdominoplasty . History prior Massive Weight Loss History use follow prescription medication : 1 . Accutane systemic retinoids within past 12 month ; 2 . Antiplatelet agent / Anticoagulants ( Coumadin , Heparin , Plavix ) ; 3 . Psychiatric drug investigator opinion would impair subject understand protocol requirement understand signing informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Ulthera® System</keyword>
	<keyword>Ultherapy® Treatment</keyword>
	<keyword>Ulthera , Inc .</keyword>
	<keyword>Ultrasound treatment skin</keyword>
</DOC>